跳至主要内容
临床试验/NCT02331589
NCT02331589已完成4 期

Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis

Chuncheon Sacred Heart Hospital0 个研究点目标入组 75 人开始时间: 2011年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
75
主要终点
Liver Enzymes

研究概览

简要总结

Background: Korea red ginseng (KRG) has anti-carcinogenic activity, anti-oxidant activity, and cancer related anti-fatigue.

Methods: Seventy five patients with non-alcoholic hepatitis were prospectively randomized to receive 3 weeks of KRG or placebo. Liver function test, pro-inflammatory cytokines, adiponectin, fatigue severity scale, and antioxidant activity were check and compared.

详细描述

Fatigue Severity Scale

We used to be KRUPP's fatigue severity scale. The survey has nine questions as following: (1) my motivation is lower, when I am fatigued (2) exercise brings on my fatigue (3) I am easily fatigued (4) fatigue interferes with my physical functioning (5) fatigue causes frequent problems for me (6) my fatigue prevents sustained physical functioning (7) fatigue interferes with carrying out certain duties and responsibilities (8) fatigue is among my 3 most disabling symptoms (9) fatigue interferes with my work, family, or social life. All subjects scored each question on a 7-point scale (1 = strongly disagree to 4 = neither disagree nor agree to 7 = strongly agree). All fatigue severity scale calculated and collected by one research nurse (C.W.K) in the Department of Internal Medicine.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • aspartate aminotransferase (AST) ≥ 50 U/L or alanine aminotransferase (ALT) ≥ 50 U/L, and Fatty liver or Hepatitis

排除标准

  • viral hepatitis, alcoholic hepatitis, autoimmune hepatitis, pancreatitis, hemochromatosis, Wilson's disease, drug induced liver injury, or cancer

研究组 & 干预措施

Korea Red Ginseng (KRG)

Active Comparator

KRG capsule (3,000 mg/day) for 3 weeks

干预措施: KRG (Korea Red ginseng) (Drug)

Placebo (for KRG)

Placebo Comparator

placebo (for KRG) for 3 weeks

干预措施: Placebo (for KRG) (Drug)

结局指标

主要结局

Liver Enzymes

时间窗: 3 weeks of KRG

aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase

次要结局

  • Pro-inflammatory Cytokine(3 weeks of KRG)
  • Fatigue as Measured by KRUPP's Fatigue Severity Scale(3 weeks of KRG)
  • Adiponectin(3 weeks of KRG)

研究者

发起方
Chuncheon Sacred Heart Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Ki Tae Suk

doctor, assistant professor

Chuncheon Sacred Heart Hospital

相似试验